tbuckley/cabot-search huggingface dataset:
Royal Medical Benevolent Fund's Christmas appeal
Authors: R. Sweetnam
Journal: BMJ (2001)

Two week rule for cancer referralsReducing waiting times from diagnosis to treatment might be more effectiveEditor-In their editorial on the two week rule for cancer referrals Jones et al discuss the fact that steps to meet the target for "urgent" referrals have led to a doubling of waiting time for "routine" cases. 1 This is exactly the result we would expect from our calculations modelling waiting times with a Monte Carlo model based on Poisson fluctuations in demand. 2 To sustain a waiting time below two weeks, capacity needs to exceed mean demand by approximately two patients a week for a wide range of values of mean demand.This applies to any appointment, including those for diagnostic and staging procedures, as well as for treatment.Applying this excess capacity to a subgroup of urgent referrals is inherently less efficient than applying it to reduce the waits for all patients.If a fast track for urgent referrals is created by transferring resources from routine cases, this is likely to lead to demand exceeding capacity for routine cases and hence to ever increasing waiting times.These calculations assume that variations are due to random fluctuations in a constant demand, which is an effective model for oncology referrals. 2There is some evidence from dermatology that reductions in waiting times lead to increase in demand, negating the benefit of increased resources. 3t might also apply to referrals for suspected cancer, in which case the extra capacity required will exceed our calculations.This effect should not apply to the number of cases of diagnosed cancer, which will be limited by the incidence of the disease.This suggests that resources may be more effectively targeted at reducing the waiting times from diagnosis to treatment than on reducing the time from referral by a general practitioner to diagnosis.
Creative Nonfiction
Journal: JAMA (1999)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
THE PUBLICATION OF SECTION WORK.
Journal: JAMA (1891)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
AIDS, autopsies, and abandonment
Authors: John C. Petricciani
Journal: JAMA (1989)

<h3>To the Editor.—</h3> Piazza et al<sup>1</sup>recently presented evidence that microlesions of the oral mucosa occur during passionate kissing and that small amounts of blood could be found in saliva. They then suggested that because of the presence of blood in saliva after passionate kissing, human immunodeficiency virus (HIV) may be transmitted by the oral route and that kissing should not be considered safe. In contrast to those conclusions, there is considerable evidence pointing toward an extremely low probability that passionate kissing contributes significantly to new HIV infections. Perhaps the most compelling fact is that the risk of infection has been consistently less than 1% in follow-up studies of health care workers who were exposed to the blood of HIV-infected persons through accidental needle sticks.<sup>2</sup>Since the risk of transmitting HIV through small amounts of blood by the direct parenteral route is so low, one would assume an
Be Your Own Philosopher
Authors: Samuel Vaisrub
Journal: JAMA (1974)

Contrary to prevailing impression, medicine's concern with ethical problems is not a by-product of recent advances in medical knowledge and skills. True, problems such as allotment of a limited organ supply among the many in need of a transplant or deciding to terminate an artificially sustained life did not exist in the past, but abortion, euthanasia, and other issues have always presented dilemmas. Some of these, such as the decision to save the life of a mother or the newborn, were even more frequent than they are now, when medical treatment makes it possible to save both. Confronted with ethical dilemmas, the physician of bygone days would generally follow familiar guidelines provided by the canons of his faith. Practically every religious denomination had its ready answers to the then existing problems. Sometimes answers might conflict with those of other denominations, sometimes they would accord. In the latter case, similar conclusions
Receptor-mediated delivery of hepatitis B virus DNA and antisense oligodeoxynucleotides to avian liver cells
Authors: J Madon
Journal: Hepatology (1996)

A highly efficient receptor-mediated delivery system for DNA and oligodeoxynucleotides (ODNs) to avian liver cells has been established, using complexes of nonmodified human adenovirus particles and a protein conjugate consisting of N-acetyl-glucosamine-modified bovine serum albumin, streptavidin, and Poly-L-lysine. The newly developed method of protein-conjugate preparation and purification yielded highly stable complexes with high DNA delivery efficiency for constructs expressing the lacZ gene, hepatitis B virus (HBV) DNA, and ODNs. Using this delivery system, an antisense ODN targeted to the encapsidation site of the HBV pregenome causes strong inhibition of HBV replication in vitro. The described, receptor-mediated DNA delivery method should prove useful for investigations of HBV replication, gene expression, and mode of action of antiviral agents in vitro, as well as for model studies of gene therapy for liver diseases from various etiologies, including viral hepatitides.
Medicine, Baltimore
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Kokopelli
Authors: Klaus F. Wellmann
Journal: JAMA (1970)

<h3>To the Editor.—</h3> In his plea (<b>214</b>: 599, 1970) for a medical explanation of the derivation of the Kokopelli figure of Indian paleology, Dr. Vogl fails to acknowledge the large body of cultural, ie, nonmedical, associations, all detailed in my article (<b>212</b>:1678, 1970), that characterize this figure and all its individual attributes such as flute, "gibbus" deformity, and phallus. In order to understand Kokopelli, a hypothesis of physical disability is, in my opinion, simply not necessary. I had also hoped to show that the great variability with which the Kokopelli figure has been depicted by its ancient creators renders it virtually impossible to invoke any one specific disease for an explanation; that is true not only for Pott's disease but would equally apply for achondroplasia and any other affliction one might be tempted to think of. As was pointed out, there are unmistakable Kokopelli figures without any gibbus deformity,
Abstract 5250: Notch signaling in ER+ breast cancer in response to endocrine therapy agents
Authors: Ciera S. Singleton, Lucio Miele, Judy S. Crabtree
Journal: Cancer Research (2019)

Abstract Breast cancer is the most frequent cancer in women in the world, and more than 70% of breast cancer cases are estrogen receptor α positive (ER+). Standard treatment for ER+ breast cancers is endocrine therapy that consists of selective estrogen receptor modulators (SERMs) such as tamoxifen in pre-menopausal patients; aromatase inhibitors (AIs); or selective estrogen receptor down-regulators (SERDs); fulvestrant, and treatment is dependent on the menopausal state of the patient. Many luminal tumors acquire resistance to therapy and recur, leading to disease progression and mortality. Resistance may result from the activation of quiescent signaling pathways that drive cancer stem cell (CSC) activity, such as the Notch signaling pathway. Previous studies demonstrate that activation of Notch via the NOTCH1 receptor recruits ERα in the absence of estrogen to facilitate transcription of estrogen responsive genes. However, NOTCH4 is often upregulated in resistant ER+ breast cancers, driving endocrine therapy resistance via breast CSC activity. We hypothesize that NOTCH4 promotes the transcription of estrogen-responsive genes in the absence of estrogen in a selective manner that is unlike NOTCH1. Understanding how NOTCH4 regulates the transcription of estrogen responsive genes upon treatment with endocrine therapy may suggest the need for combination therapy for ER+ breast cancer that includes a Notch targeted therapy. We have measured mRNA expression of classic estrogen responsive genes in ER+ breast cancer cell lines that either overexpress NOTCH1 or NOTCH4. Our data demonstrate differential expression of estrogen-responsive genes between NOTCH1 and NOTCH4 in the presence of tamoxifen. We have also measured Notch contribution to breast cancer stem cell activity through mammosphere formation assays using ER+ breast cancer cell lines in the presence of fulvestrant and Notch signaling inhibitors. The expression of classical estrogen responsive genes from mammospheres was altered in the presence of fulvestrant, Notch signaling inhibitors, or combinations of the two treatments. Further, combination treatment led to the disruption of mammosphere formation suggesting that combination therapy in the clinic may be suitable for the prevention of endocrine resistance by inhibition of BCSC activity through NOTCH4. Citation Format: Ciera S. Singleton, Lucio Miele, Judy S. Crabtree. Notch signaling in ER+ breast cancer in response to endocrine therapy agents [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 5250.
Voprosy Virusologii, Moscow
Journal: JAMA (1967)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Equestrian injuries. Results of a prospective study
Authors: J. A. Grossman
Journal: JAMA (1978)

In a prospective study involving 110 injured equestrians, there were no noteworthy correlations between age, sex, or experience of the amateur riders and injury occurrence. Tack failure caused several injuries. Among fox hunters the incidence was related only to frequency of hunts. The most common severe injury was to the head, associated with lack of headgear. Fewer than 20% of the 110 riders used a protective helmet. There were four renal contusions and one bladder laceration. The most frequent injuries were fractures of the upper extremities. Wearing a good-quality protective helmet and checking tack are important for injury prevention. (<i>JAMA</i>240:1881-1882, 1978)
Nitrate tolerance impairs nitric oxide-mediated vasodilation in vivo
Authors: J. Bech Laursen, S. Boesgaard, H. Enghusen Poulsen, J. Aldershvile
Journal: Cardiovascular Research (1996)

ObjectivesNitroglycerin (NTG) is metabolized to nitric oxide (NO) in vascular smooth muscle cells. It is currently not clear whether prolonged exposure to NTG and tolerance development directly affects endogenous NO-mediated vasodilation in vivo. This study investigates NO-mediated vasodilation in conscious chronically catheterized rats before and after development of nitrate tolerance. The effect of the thiol compound N-acetylcysteine (NAC), which may affect NTG responsiveness, was also studied.
Special Contribution
Journal: JAMA (1962)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
GONORRHEAL SEPTICEMIA AND ULCERATIVE ENDOCARDITIS.
Journal: JAMA (1899)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
THE UNWELCOME "EX."
Journal: JAMA (1896)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
US military medical teams begin third year of United Nations support in war-torn Balkans
Authors: P. Gunby
Journal: JAMA (1994)

TOMORROW marks the beginning of the third year for US military medicine's operation of the United Nations (UN) hospital in the former republic of Yugoslavia. It was November 10, 1992, when an advance team of medical and support personnel from the 212th Mobile (US) Army Surgical Hospital (MASH) arrived in Zagreb, Croatia, from Germany to set up the facility at Camp Pleso near the city's airport to care for UN peacekeepers. The 502nd MASH, also from US Army posts in Germany, Belgium, and Italy, succeeded the 212th MASH 6 months later. The US Air Force's 48th Medical Group Hospital from RAF (Royal Air Force base) Lakenheath, England, then operated the Zagreb facility from September 1993 until the US Navy's Fleet Hospital 6 took over March 17 (<i>JAMA</i>. 1994;271:894). Another US Navy mobile medical unit, Fleet Hospital 5, arrived 11 weeks ago and will operate the UN facility until mid-February 1995.
The efficacy and safety of XELOX plus bevacizumab with oxaliplatin stop-and-go strategy in first-line treatment for metastatic colorectal cancer: CCOG 0902 study.
Authors: Takuya Watanabe, Goro Nakayama, Kiyoshi Ishigure, Naomi Hayashi, Toyohisa Yaguchi, Hiroshi Kojima, Kenji Tsuboi, Akihiro Ito, Tomohiro Deguchi, Masanori Sekiya, Chie Tanaka, Yuichi Ando, Norifumi Ohashi, Yasuhiro Kodera
Journal: Journal of Clinical Oncology (2013)

564 Background: XELOX plus bevacizumab (BEV) is an established first-line therapy for metastatic colorectal cancer (mCRC). However, the cumulative neurotoxicity of oxaliplatin often requires therapy to be discontinued while the patient is still responding. The aim of this study was to evaluate efficacy and safety of XELOX plus BEV with oxaliplatin stop and go strategy. Methods: Fifty four patients with unresectable mCRC were enrolled as first-line treatment. They were treated with four cycles of XELOX plus BEV, followed by maintenance therapy with capecitabine (Cape) plus BEV. Reintroduction of oxaliplatin was scheduled after eight cycles of Cape plus BEV or upon tumor progression. The primary endpoint was progression free survival (PFS). Results: Forty nine patients (90%) achieved to the maintenance therapy and thirty one patients (59%) were reintroducted oxaliplatin. The response rates and disease control rates were 57% and 96% in the initial XELOX plus BEV, 6.1% and 73% in Cape plus BEV maintenance therapy. Median PFS in initial XELOX plus BEV was 11.0 months (95%CI: 7.8-14.1). One year survival rate was 86%. Conclusions: XELOX plus BEV was feasible as a first line treatment with mCRC. The most cases achieved disease control during Cape plus BEV maintenance therapy. Clinical trial information: UMIN000006478.